Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics reported a private placement of pre-funded warrants to raise capital and provided related registration rights and disclosures. The company sold pre-funded warrants to purchase up to 5,231,090 shares of common stock at a purchase price of $16.249 per pre-funded warrant, with each warrant exercisable for $0.001 per share and not expiring. The company agreed to file a registration statement for resale of the shares within 60 days of closing and to use reasonable best efforts to have it declared effective within 75 days of initial filing. The filing states the securities were sold without registration and only to accredited investors for investment purposes. Exhibits include forms of the warrant, purchase agreement and registration rights agreement, plus press releases announcing the private placement and MZE782 data dated September 11, 2025. The filing also contains standard forward-looking statement language identifying programs MZE829 and MZE782 and listing development, regulatory, funding and macroeconomic risks.
Tahir Misbah, Chief Financial Officer of Maze Therapeutics, Inc. (MAZE), was granted a stock option for 325,000 shares with an exercise price of $15.32. The Form 4 reports the option award dated 09/02/2025 and shows 325,000 shares beneficially owned following the transaction as a direct holding. The option includes a vesting schedule: 1/4 of the award vests on September 2, 2026, then 1/48th of the total award vests monthly thereafter, subject to continued service. The filing is signed by an attorney-in-fact on behalf of the reporting person and reports the transaction under Section 16.
Tahir Misbah, identified as Chief Financial Officer and a director of Maze Therapeutics, Inc. (Ticker: MAZE), submitted an initial Form 3 reporting his beneficial ownership status. The filing states no securities are beneficially owned by the reporting person. The form was executed through an attorney-in-fact signature on the submitted document.
Maze Therapeutics announced the appointment of Misbah Tahir as Chief Financial Officer and principal financial officer, effective September 2, 2025. The company disclosed key compensation terms in an offer letter: an initial annual base salary of $500,000, an annual discretionary bonus opportunity up to 40% of base salary, a one-time sign-on bonus of $50,000 (subject to clawback if service is under one year), and an equity option to purchase up to 325,000 shares that vests 25% after one year and then 1/48th monthly thereafter. The filing notes the appointment relates to Maze's Form 10-Q for the quarter ending September 30, 2025.
Maze Therapeutics director Neil Exter reported acquisition of an option to purchase 16,000 shares of Maze Therapeutics, Inc. (MAZE). The option has an exercise price of $13.35 and was reported with a transaction date of 08/17/2025. The option becomes exercisable beginning 08/16/2035 per the table, and 16,000 underlying shares are associated with the award. The filing explains the option vests monthly after an initial partial vesting of 1/16th on March 3, 2025, subject to continued service. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Frazier Life Sciences funds report material holdings in Maze Therapeutics common stock. Frazier Life Sciences Public Fund, L.P. directly holds 3,352,915 shares, equal to 7.7% of the outstanding class. Other reporting entities include Frazier Life Sciences Public Overage Fund, L.P. with 989,351 shares (2.3%), Frazier Life Sciences X, L.P. with 75,982 shares (0.2%), and Frazier Life Sciences XI, L.P. with 149,026 shares (0.3%). Percentages are calculated using 43,797,166 shares outstanding as reported by the issuer.
The filing clarifies voting and dispositive arrangements: several entities report shared voting and dispositive power over the disclosed shares, and James N. Topper and Patrick J. Heron share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The Statement expressly corrects prior attributions and overstatements of beneficial ownership for certain members and includes a certification that the securities are not held for the purpose of changing or influencing control of the issuer.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 2,625,089 shares of Maze Therapeutics common stock, representing 6.0% of the outstanding class. The filing shows no sole voting or dispositive power and discloses shared voting and dispositive power over those shares, indicating the position is managed collectively rather than controlled by a single entity. The reporting person is classified as an investment adviser (IA, HC), and the filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control.
The filing further identifies indirect subsidiaries as the operating vehicles that acquired the securities and includes a power of attorney authorizing firm personnel to file ownership reports on the company’s behalf.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report joint beneficial ownership of 3,948,910 shares of Maze Therapeutics common stock, which the statement says represents 9.02% of the outstanding common shares. The holders report shared voting and shared dispositive power over those shares and no sole voting or dispositive power.
The ownership percentage is calculated from 43,797,166 shares outstanding per the issuer's public disclosures. The filing includes a certification that the shares were not acquired to change or influence control of the issuer and identifies Deep Track Capital, LP as the relevant entity for which David Kroin may be considered a control person.
Maze Therapeutics reported widening operating losses as it advances clinical programs while strengthening its balance sheet through an IPO and earlier licensing deals. For the quarter ended June 30, 2025 the company recorded a net loss of $33.7 million and a six‑month loss of $66.5 million, driven by higher research and development and public‑company costs. Research and development expense rose to $28.1 million for the quarter from $19.5 million a year earlier, reflecting clinical and manufacturing progression of lead programs.
The company completed an initial public offering that generated net proceeds of approximately $127.8 million, and held $264.5 million in cash and cash equivalents as of June 30, 2025, which management says is sufficient to fund operations for at least one year. In 2024 Maze recognized $165.0 million of license revenue from three agreements, including a $150.0 million upfront from Shionogi. The balance sheet now reflects elimination of redeemable convertible preferred stock after conversion to common shares. Overall, Maze is a clinical‑stage biotech investing heavily in R&D with one year of disclosed liquidity and no product revenue from sales.
Maze Therapeutics, Inc. reported that on August 12, 2025 it issued a press release reporting its financial results for the second quarter ended June 30, 2025. The filing states the full text of that press release is furnished as Exhibit 99.1 to this Current Report. The Company notes that the information in Item 2.02, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or subject to certain liabilities under the Securities Act. The Form 8-K identifies the registrant as Maze Therapeutics, Inc., lists its Nasdaq trading symbol MAZE, shows Delaware as its jurisdiction of incorporation, and indicates it is an emerging growth company.